United Capital Financial Advisers, LLC Uni Qure N.V. Transaction History

United Capital Financial Advisers, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$29.24 - $42.03 $849,977 - $1.22 Million	-29,069 Closed	0 $0
Q4 2020 Feb 17, 2021	SELL	$35.35 - $50.67 $130,052 - $186,414	-3,679 Reduced 11.23%	29,069 $1.05 Million
Q3 2020 Nov 13, 2020	SELL	$35.98 - $47.66 $19,860 - $26,308	-552 Reduced 1.66%	32,748 $1.21 Million
Q2 2020 Aug 13, 2020	BUY	$45.06 - $67.74 $1.5 Million - $2.26 Million	33,300 New	33,300 $1.5 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on United Capital Financial Advisers, LLC with notifications on news.